JCT  Vol.4 No.2 , April 2013
Radiotherapy and Chemotherapy in T2N0 Glottic Cancer: Does Chemotherapy Improve Local Control?
ABSTRACT

Purpose: To compare concurrent chemoradiotherapy with radiotherapy in T2N0 glottic cancer. Materials and Methods: Thirty nine patients were treated with radiotherapy alone. In detail, 30 patients treated between 1985 and 1995, and 9 patients treated between 1995 and 2010 were included in the radiotherapy alone group. Between 1995 and 2010, 22 patients were treated with concurrent chemoradiotherapy. Conventional fractionation was applied in 19 patients in the radiotherapy group and in 1 patient in the chemoradiotherapy group. Hyperfractionation was applied to 20 patients in the radiotherapy group and to 21 patients in the chemoradiotherapy group. Total dose ranged from 64 Gy to 76.8 Gy in the radiotherapy group and from 66 Gy to 76.8 Gy in the chemoradiotherapy group. Cisplatin or carboplatin was administered in the chemoradiotherapy group. Results: There were no differences in the 5-year preservation rate of vocal function (82.8% vs 87.4%, p = 0.652), local control rate (77.2% vs 92.9%, p = 0.163), and 5-year overall survival rate (86.4% vs 90.2%, p = 0.497) between the radiotherapy and chemoradiotherapy groups. Conclusion: In T2N0 glottic cancer, no difference was observed between radiotherapy alone and concurrent chemoradiotherapy groups.


Cite this paper
T. Kosugi, K. Suzuki, K. Konishi, H. Nonaka and H. Mineta, "Radiotherapy and Chemotherapy in T2N0 Glottic Cancer: Does Chemotherapy Improve Local Control?," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 513-517. doi: 10.4236/jct.2013.42063.
References
[1]   D. G. Pfister, S. A. Laurie, G. S. Weinstein, W. M. Mendenhall, D. J. Adelstein, K. K. Ang, et al., “American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer,” Journal of Clinical Oncology, Vol. 24, No. 22, 2006, pp. 3693-3704. doi:10.1200/JCO.2006.07.4559

[2]   E. Cellai, P. Frata, S. M. Magrini, F. Paiar, R. Barca, S. Fondelli, et al., “Radical Radiotherapy for Early Glottic Cancer: Results in a Series of 1087 Patients from Two Italian Radiation Oncology Centers. I. The Case of T1N0 Disease,” International Journal of Radiation Oncology *Biology*Physics, Vol. 63, No. 5, 2005, pp. 1378-1386. doi:10.1016/j.ijrobp.2005.05.018

[3]   P. Frata, E. Cellai, S. M. Magrini, B. Bonetti, E. Vitali, S. Tonoli, et al., “Radical Radiotherapy for Early Glottic Cancer: Results in a Series of 1087 Patients from Two Italian Radiation Oncology Centers. II. The Case of T2N0 Disease,” International Journal of Radiation Oncology *Biology*Physics, Vol. 63, No. 5, 2005, pp. 1378-1394. doi:10.1016/j.ijrobp.2005.05.013

[4]   L. H. Sobin and C. Wittekind, “International Union against Cancer (UICC) TNM Classification of Malignant Tumours,” 6th Edition, Wiley, New York, 2002.

[5]   Eastern Cooperative Oncology Group (ECOG) Performance Status.

[6]   A. H. Calvert, D. R. Newell, L. A. Gumbrell, S. O’Reilly, M. Burnell, F. E. Boxall, et al., “Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function,” Journal of Clinical Oncology, Vol. 7, No. 11, 1989, pp. 1748-1756.

[7]   National Cancer Institute, “Common Terminology Criteria for Adverse Events v4.0,” http://ctep.cancer.gov/protocolDeve lopment/electronicapp- lications/ctc.htm

[8]   R Foundation for Statistical Computing, “Free Software,” http://www.r-project.org

[9]   E. L. Kaplan and P. Meier, “Non-Parametric Estimation from Incomplete Observations,” Journal of the American Statistical Association, Vol. 53, No. 282, 1958, pp. 457-481. doi:10.1080/01621459. 1958.10501452

[10]   T. Akimoto, T. Nonaka, Y. Kitamoto, H. Ishikawa, H. Ninomiya, K. Chikamatsu, et al., “Radiation Therapy for T2N0 Laryngeal Cancer: A Retrospective Analysis for the Impact of Concurrent Chemotherapy on Local Control,” International Journal of Radiation Oncology*Biology* Physics, Vol. 64, No. 4, 2006, pp. 995-1001. doi:10.1016/j.ijrobp.2005.10.003

[11]   Y. Kumamoto, M. Masuda, Y. Kuratomi, S. Toh, A. Shinokuma, K. Chujo, et al., “FAR” Chemoradiotherapy Improves Laryngeal Preservation Rates in Patients with T2N0 Glottic Carcinoma,” Head & Neck, Vol. 24, No. 7, 2002, pp. 637-642. doi:10.1002/hed.10114

[12]   Y. Itoh and N. Fuwa, “Retrospective Analysis: Concurrent Chemoradiotherapy Using Protracted Continuous Infusion of Low-Dose Cisplatin and 5-Fluorouracil for T2N0 Glottic Cancer,” Radiation Medicine, Vol. 24, No. 4, 2006, pp. 277-281. doi:10.1007/s11604-005-1517-1

[13]   M. Nakayama, K. Hayakawa, M. Okamoto, Y. Niibe, H. Ishiyama and S. Kotani, “Phase I/II Trial of Concurrent Use of S-1 and Radiation Therapy for T2 Glottic Cancer,” Japanese Journal of Clinical Oncology, Vol. 40, No. 10, 2010, pp. 921-926. doi:10.1093/jjco/hyq077

[14]   A. B. Karim, J. H. Kralendonk, L. Y. Yap, K. H. Njo, A. H. Tierie, R. M. Tiwari, et al., “Heterogeneity of Stage II Glottic Carcinoma and Its Therapeutic Implications,” International Journal of Radiation Oncology*Biology*Physics, Vol. 13, No. 3, 1987, pp. 313-317. doi:10.1016/0360-3016(87)90004-6

[15]   S. P. Reddy, R. L. Hong, S. Nagda and B. Emami, “Effect of Tumor Bulk on Local Control and Survival of Patients with T1 Glottic Cancer: A 30-Year Experience,” International Journal of Radiation Oncology*Biology*Physics, Vol. 69, No. 5, 2007, pp. 1389-1394. doi:10.1016/j.ijrobp.2007.05.077

[16]   E. D. McCoul and G. Har-El, “Meta-Analysis of Impaired Vocal Cord Mobility as a Prognostic Factor in T2 Glottic Carcinoma,” JAMA Otolaryngology—Head & Neck Surgery, Vol. 135, No. 5, 2009, pp. 479-486. doi:10.1001/archoto.2009.47

[17]   H. Haugen, K. A. Johansson and C. Mercke, “Hyperfractionated-Accelerated or Conventionally Fractionated Radiotherapy for Early Glottic Cancer,” International Journal of Radiation Oncology*Biology*Physics, Vol. 52, No. 1, 2002, pp. 109-119. doi:10.1016/S0360-3016(01)01812-0

[18]   H. Tsuji, T. Kiba, M. Nagata, T. Inoue, H. Yukawa, T. Yamashita, et al., “A Phase I Study of Concurrent Chemoradiotherapy with S-1 for T2N0 Glottic Carcinoma,” Oncology, Vol. 71, No. 5-6, 2006, pp. 369-373. doi:10.1159/000108385

 
 
Top